[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@Mike182035](/creator/twitter/Mike182035)
"#AVCT This is actually also part of the arguement for BP to partner rather than early takeover The former a cheaper method of backing both horses"  
[X Link](https://x.com/Mike182035/status/1980905318562574547) [@Mike182035](/creator/x/Mike182035) 2025-10-22T07:53Z XX followers, 1411 engagements


"#AVCT Not allowed to reply Jason But tbh I think practically all serious pharma are contenders And I am being serious too"  
[X Link](https://x.com/Mike182035/status/1980967079055409193) [@Mike182035](/creator/x/Mike182035) 2025-10-22T11:58Z XX followers, 2915 engagements


"#AVCT There is very little doubt that all relevant Pharma are aware of Avacta - it's just a non topic She's an ex Avacta employee I believe"  
[X Link](https://x.com/Mike182035/status/1980975279993389523) [@Mike182035](/creator/x/Mike182035) 2025-10-22T12:31Z XX followers, 2193 engagements


"#AVCT 2/n "4. Illustrative ExampleImagine AVA6207 in pancreatic cancer (KRAS-driven mito-addicted):Primary Warhead: Exatecan (topo I inhibitor) causes DNA breaks killing proliferative cells. Mito-Warhead: Venetoclax (BCL-2 inhibitor) hits mitochond.""  
[X Link](https://x.com/Mike182035/status/1981429999996482036) [@Mike182035](/creator/x/Mike182035) 2025-10-23T18:38Z XX followers, XXX engagements


"#AVCT Don't you mean $bns question Ben It's a guess but I have a suspicion this development will shortly be shown to be funded"  
[X Link](https://x.com/Mike182035/status/1977702794661412914) [@Mike182035](/creator/x/Mike182035) 2025-10-13T11:47Z XX followers, 1255 engagements


"#AVCT 3/n ".mitochondria releasing cytochrome c and collapsing m. This:Sensitizes: Lowers apoptosis threshold so exatecans DNA damage triggers faster cell death. Blocks Resistance: Prevents OXPHOS/BCL-2 upregulation in hypoxic stem cells which would otherwise." ""  
[X Link](https://x.com/Mike182035/status/1981431236120985968) [@Mike182035](/creator/x/Mike182035) 2025-10-23T18:43Z XX followers, XXX engagements


"#AVCT ".Verdict: The triple-warhead construct is the stronger contender for CSC-driven TNBC leveraging mito-specificity to tackle relapse (40-50% vs. XX% CSC kill) but its longer timeline (9-11 vs. 8-9 years) and tox risks make the dual-warhead a safer faster bet for .""  
[X Link](https://x.com/Mike182035/status/1981450579667792226) [@Mike182035](/creator/x/Mike182035) 2025-10-23T20:00Z XX followers, XXX engagements


"#AVCT ".market entry. Triples edge shines in refractory settings aligning with Avactas 2025 vision (AVA6207s CSC focus) and . mito-expertise. Monitor Avactas October XX 2025 investor update for triple-warhead hints." Usual AI caveats - garbage in garbage out"  
[X Link](https://x.com/Mike182035/status/1981451208914035112) [@Mike182035](/creator/x/Mike182035) 2025-10-23T20:02Z XX followers, XXX engagements